Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Free Cash Flow (2016 - 2025)

Seres Therapeutics' Free Cash Flow history spans 11 years, with the latest figure at $2.4 million for Q3 2025.

  • For Q3 2025, Free Cash Flow rose 106.98% year-over-year to $2.4 million; the TTM value through Sep 2025 reached -$23.4 million, up 85.19%, while the annual FY2024 figure was -$149.0 million, 18.88% down from the prior year.
  • Free Cash Flow for Q3 2025 was $2.4 million at Seres Therapeutics, up from -$13.4 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $123.6 million in Q3 2021 and bottomed at -$80.7 million in Q1 2023.
  • The 5-year median for Free Cash Flow is -$39.7 million (2024), against an average of -$25.9 million.
  • The largest YoY upside for Free Cash Flow was 572.58% in 2021 against a maximum downside of 196.68% in 2021.
  • A 5-year view of Free Cash Flow shows it stood at -$53.4 million in 2021, then fell by 1.25% to -$54.1 million in 2022, then grew by 10.59% to -$48.4 million in 2023, then increased by 18.87% to -$39.2 million in 2024, then skyrocketed by 106.17% to $2.4 million in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Free Cash Flow are $2.4 million (Q3 2025), -$13.4 million (Q2 2025), and $26.9 million (Q1 2025).